Fedora Pharmaceuticals Appoints Thomas R. Parr, Ph.D., Chief ...


Dec 1, 2012 (5 years and 5 months ago)


For Immediate Release

CONTACTS: Sameeh Salama Aline Schimmel
Fedora Pharmaceuticals Scienta Communications
780-989-9826 312-238-8957
info@fedorapharma.com aschimmel@scientapr.com

Fedora Pharmaceuticals, Inc. 4290-91A Street
ph: 780-989-9845 www.fedorapharma.com Edmonton, AB
info@fedorapharma.com Canada T6E 5V2

Fedora Pharmaceuticals Appoints Thomas R. Parr, Ph.D., Chief Scientific Officer

EDMONTON, Alberta – September 5, 2012 – Fedora Pharmaceuticals, Inc. today announced the
appointment of
Thomas Parr, Ph.D.
to the newly created role of chief scientific officer. Dr. Parr was most
recently chief scientific officer at Targanta Therapeutics, where he was instrumental in the development
of oritavancin, a lipoglycopeptide for the treatment of Gram-positive bacterial infections.

Christopher Micetich
, chief executive officer and founder of Fedora Pharmaceuticals stated, “Tom has
worked in the infectious disease space for more than two decades and has broad corporate experience
in start-up, public biotechnology and large pharmaceutical companies. This industry knowledge will be
invaluable as Fedora, a newly incorporated biotechnology company, advances its first beta-lactam
inhibitor candidates through preclinical development and into clinical trials.”

Prior to joining Fedora pharmaceuticals, Dr. Parr served as Targanta Therapeutics chief scientific officer
until the company’s acquisition by The Medicines Company. Earlier, Dr. Parr worked in various senior
capacities at private biopharmaceutical companies Adaptive Therapeutics, Embiosis Pharmaceuticals
(formerly MicroGenomics, Inc.), Xenogen Corporation, Intrabiotics Pharmaceuticals, Inc. and Microcide
Pharmaceuticals. Before committing to smaller biotech companies, Dr. Parr was a senior research
scientist at Eli Lilly and Company. During his career, Dr. Parr worked on a broad range of marketed
antibiotics including beta-lactams, glycopeptides, lipodepsipeptides, quinolones, macrolides,
echinocandins and a variety of other chemical classes. Dr. Parr received his Ph.D. in microbiology and
infectious diseases from The University of Calgary with Professor L. E. Bryan and he was a postdoctoral
fellow with Dr. R. E. W. Hancock at the University of British Columbia. He also holds a Master of Arts in
philosophy and a Bachelor of Arts in biology and philosophy.

“Having worked, as Chris noted, in the infectious disease industry for most of my career, I have seen
both the great potential of antibiotics and the incredible damage caused by antibiotic resistance,” added
Dr. Parr. “The beta-lactamase inhibitors being developed at Fedora have the potential to address the
increasingly common and costly issue of beta-lactam resistance. I look forward to working with the team
here at Fedora to advance these compounds through preclinical and into clinical development.”

Antibiotic resistance and beta

Over time, bacteria have evolved a resistance to
beta-lactam antibiotics
through the production of beta-
lactamases – enzymes that cleave the beta-lactam ring structure that is common to their molecular
structure, thereby inhibiting their antibiotic activity. Beta‑lactam antibiotics, which include penicillin

Fedora Pharmaceuticals, Inc. 4290-91A Street
ph: 780-989-9845 www.fedorapharma.com Edmonton, AB
info@fedorapharma.com Canada T6E 5V2
derivatives, cephalosporins, monobactams and carbapenems, have broad utility in the treatment of
either Gram-negative or Gram-positive bacteria and as such have been estimated to comprise 65% of
the antibiotics market worldwide. It is therefore critical that resistance to beta‑lactam antibiotics be

First-generation beta-lactamase inhibitors, first introduced in the 1980s, were an important advance and
have seen strong market adoption. However, their activity against only one of the four classes of beta-
lactamases has limited their potential.

About Fedora Pharmaceuticals
Fedora Pharmaceuticals is developing a family of beta-lactamase inhibitors designed to have activity
against pathogens containing all four classes of beta-lactamases. These and potentially other beta-
lactamase inhibitors will be developed by Fedora for use in combination with various beta-lactam
antibiotics to treat those antibiotic infections currently resistant to therapy. Fedora Pharmaceuticals is in
the lead optimization stage of preclinical development with its first beta-lactamase inhibitor candidates,
and anticipates entering IND-enabling studies in 2013. Fedora was founded in 2012 and is
headquartered in Edmonton, Alberta, Canada. For more information on the company, please visit